Shetzline Michael's Form 4 filing
Ironwood Pharmaceuticals Inc (IRWD) · filed Mar 2, 2022
- Accession no.
- 0001209191-22-014652
- Filed
- Mar 2, 2022
- Trade date
- Feb 28, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions. Open-market sales total $189.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Shetzline MichaelCIK 0001808509 | Officer (CMO,SVP,Head-Res&Drug) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 28, 2022 | Class A Common Stock | SSaleDisposed | −1,367 | $10.77 | −$14,722.59 | 211,620 | Direct | |
| Feb 28, 2022 | Class A Common Stock | SSaleDisposed | −2,911 | $10.77 | −$31,351.47 | 208,709 | Direct | |
| Feb 28, 2022 | Class A Common Stock | SSaleDisposed | −5,161 | $10.77 | −$55,583.97 | 203,548 | Direct | |
| Feb 28, 2022 | Class A Common Stock | SSaleDisposed | −3,804 | $10.77 | −$40,969.08 | 199,744 | Direct | |
| Feb 28, 2022 | Class A Common Stock | SSaleDisposed | −4,364 | $10.77 | −$47,000.28 | 195,380 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.